Intervention Review

You have free access to this content

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children

  1. Tea Andabaka1,*,
  2. Jason W Nickerson2,
  3. Maria Ximena Rojas-Reyes3,
  4. Juan David Rueda4,
  5. Vesna Bacic Vrca5,
  6. Bruno Barsic6

Editorial Group: Cochrane Acute Respiratory Infections Group

Published Online: 30 APR 2013

Assessed as up-to-date: 8 AUG 2012

DOI: 10.1002/14651858.CD006602.pub4


How to Cite

Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD006602. DOI: 10.1002/14651858.CD006602.pub4.

Author Information

  1. 1

    Ewopharma Ltd, Zagreb, Croatia

  2. 2

    Institute of Population Health, Ottawa, Ontario, Canada

  3. 3

    Pontificia Universidad Javeriana, Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Bogota, DC, Colombia

  4. 4

    Pontificia Universidad Javeriana, Departamento de Cirugía, Bogota, Cundinamarca, Colombia

  5. 5

    University Hospital Dubrava, Department of Hospital Pharmacy, Zagreb, Croatia

  6. 6

    University of Zagreb, School of Medicine, Hospital for Infectious Diseases, Department of Intensive Care, Zagreb, Croatia

*Tea Andabaka, Ewopharma Ltd, Zadarska 80 / 2, Zagreb, 10000, Croatia. Tea.Andabaka@gmail.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 30 APR 2013

SEARCH

[Figure 1]
Figure 1. Forest plot of comparison: 1 Palivizumab versus placebo, outcome: 1.1 Hospitalisation for RSV infection.
[Figure 2]
Figure 2. Forest plot of comparison: 1 Palivizumab versus placebo, outcome: 1.4 Admission to ICU.
[Figure 3]
Figure 3. Forest plot of comparison: 1 Palivizumab versus placebo, outcome: 1.11 Number of children reporting any SAE.
[Figure 4]
Figure 4. Forest plot of comparison: 2 Palivizumab versus motavizumab, outcome: 2.1 Hospitalisation for RSV infection.
[Figure 5]
Figure 5. Forest plot of comparison: 2 Palivizumab versus motavizumab, outcome: 2.2 RSV-specific outpatient MALRI.
[Figure 6]
Figure 6. Forest plot of comparison: 2 Palivizumab versus motavizumab, outcome: 2.7 Mechanical ventilation for RSV infection.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Palivizumab versus placebo, Outcome 1 Hospitalisation for RSV infection.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Palivizumab versus placebo, Outcome 2 All-cause mortality.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Palivizumab versus placebo, Outcome 3 Total RSV hospital days per 100 children.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Palivizumab versus placebo, Outcome 4 Admission to ICU.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Palivizumab versus placebo, Outcome 5 Days in the ICU per 100 children.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Palivizumab versus placebo, Outcome 6 Mechanical ventilation for RSV infection.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Palivizumab versus placebo, Outcome 7 Days of mechanical ventilation per 100 children.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Palivizumab versus placebo, Outcome 8 Days of supplemental oxygen therapy per 100 children.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Palivizumab versus placebo, Outcome 9 Number of children reporting any AE.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Palivizumab versus placebo, Outcome 10 Number of children reporting related AE.
[Analysis 1.11]
Analysis 1.11. Comparison 1 Palivizumab versus placebo, Outcome 11 Number of children reporting any SAE.
[Analysis 1.12]
Analysis 1.12. Comparison 1 Palivizumab versus placebo, Outcome 12 Number of children reporting related SAE.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Palivizumab versus motavizumab, Outcome 1 Hospitalisation for RSV infection.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Palivizumab versus motavizumab, Outcome 2 RSV-specific outpatient MALRI.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Palivizumab versus motavizumab, Outcome 3 All-cause mortality.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Palivizumab versus motavizumab, Outcome 4 Total RSV hospital days per 100 children.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Palivizumab versus motavizumab, Outcome 5 Admission to ICU.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Palivizumab versus motavizumab, Outcome 6 Days in the ICU per 100 children.
[Analysis 2.7]
Analysis 2.7. Comparison 2 Palivizumab versus motavizumab, Outcome 7 Mechanical ventilation for RSV infection.
[Analysis 2.8]
Analysis 2.8. Comparison 2 Palivizumab versus motavizumab, Outcome 8 Days of mechanical ventilation per 100 children.
[Analysis 2.9]
Analysis 2.9. Comparison 2 Palivizumab versus motavizumab, Outcome 9 Supplemental oxygen therapy for RSV infection.
[Analysis 2.10]
Analysis 2.10. Comparison 2 Palivizumab versus motavizumab, Outcome 10 Days of supplemental oxygen therapy per 100 children.
[Analysis 2.11]
Analysis 2.11. Comparison 2 Palivizumab versus motavizumab, Outcome 11 Number of children reporting any AE.
[Analysis 2.12]
Analysis 2.12. Comparison 2 Palivizumab versus motavizumab, Outcome 12 Number of children reporting related AE.
[Analysis 2.13]
Analysis 2.13. Comparison 2 Palivizumab versus motavizumab, Outcome 13 Number of children reporting any SAE.
[Analysis 2.14]
Analysis 2.14. Comparison 2 Palivizumab versus motavizumab, Outcome 14 Number of children reporting related SAE.